Uncovering Chromatin Remodeling & ALT Vulnerabilities: Targeting ALC1 and FANCM to Advance Biomarker-Driven Synthetic Lethality
- Demonstrating how ALC1 inhibition enhances PARP trapping and PARP inhibitor responses in HR-deficient cancers
- Establishing FANCM dependency as a therapeutic vulnerability in ALT-positive tumors, unlocking new synthetic lethality opportunities
- Highlighting biomarker strategies to identify HR-deficient and ALT-driven patients for precision deployment of ALC1 and FANCM–targeted therapies